Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Ophthalmology. 2021 Jun;128(6):920-927. doi: 10.1016/j.ophtha.2020.10.028. Epub 2020 Dec 24.
To review the published literature assessing the efficacy and safety of in-office probing compared with facility-based probing to treat congenital nasolacrimal duct obstruction (NLDO).
Literature searches were conducted in March 2020 in the PubMed database with no date restrictions and limited to studies published in English and in the Cochrane Library database with no restrictions. The combined searches yielded 281 citations. Of these, 21 articles were deemed appropriate for inclusion in this assessment and assigned a level of evidence rating by the panel methodologist. Four articles were rated level I, 2 articles were rated level II, and 15 articles were rated level III.
Treatments consisted of observation, in-office nasolacrimal probing, or facility-based nasolacrimal probing. Success rates and complications or recurrences were recorded from 1 week to 6 months after surgery. Complete resolution of symptoms after surgery ranged from 66% to 95.6% for office-based procedures versus 50% to 97.7% for facility-based procedures. Level I evidence indicated that 66% of cases spontaneously resolved after 6 months of observation in infants between 6 and 10 months of age. Success rates for in-office probing were lower for bilateral than for unilateral NLDO (67% vs. 82%), whereas success rates were high in both unilateral (83%) and bilateral (82%) patients who underwent facility-based probing after 6 months of observation. Cost data did not indicate a definitive cost savings of either treatment method ($562 for in-office vs. $701 for facility-based, depending on cost models predicting spontaneous resolution rates at different ages). No serious adverse events with treatment or anesthesia were reported for either treatment method.
Evidence supports the efficacy and safety of both in-office and facility-based surgery for congenital NLDO. However, treating bilateral NLDO in a facility setting may be better. Because a significant percentage of children achieved resolution spontaneously before 12 months of age, deferring treatment until 12 to 18 months of age is a reasonable option. Additional research may address symptom burden on families and the impact of anesthesia and emotional trauma of nonsedated office probings on patients and may explore further the cost of treatment for each treatment method.
回顾评估经门诊探通术与在医疗机构探通术治疗先天性鼻泪管阻塞(NLDO)的疗效和安全性的文献。
2020 年 3 月,研究人员在 PubMed 数据库中进行了文献检索,未设置时间限制,且仅检索在 Cochrane 图书馆数据库中发表的英文文献。联合检索共产生 281 条引文。其中,21 篇文章被认为适合纳入本评估,并由小组方法学家进行了证据水平分级。4 篇文章被评为 I 级,2 篇文章被评为 II 级,15 篇文章被评为 III 级。
治疗方法包括观察、门诊鼻泪管探通术或医疗机构鼻泪管探通术。术后 1 周至 6 个月记录手术成功率和并发症或复发情况。术后症状完全缓解率为门诊手术 66%至 95.6%,医疗机构手术 50%至 97.7%。I 级证据表明,6 至 10 月龄婴儿观察 6 个月后,66%的病例可自发缓解。双侧 NLDO 患者的门诊探通术成功率低于单侧 NLDO(67%比 82%),而在观察 6 个月后行医疗机构探通术的单侧(83%)和双侧(82%)患者的成功率均较高。成本数据并未表明两种治疗方法具有明确的成本节约(根据不同年龄预测自发缓解率的成本模型,门诊治疗费用为 562 美元,医疗机构治疗费用为 701 美元)。两种治疗方法均未报告与治疗或麻醉相关的严重不良事件。
证据支持经门诊和医疗机构手术治疗先天性 NLDO 的疗效和安全性。然而,在医疗机构治疗双侧 NLDO 可能更好。因为有相当比例的儿童在 12 个月龄前自发缓解,因此将治疗推迟至 12 至 18 个月龄是合理的选择。进一步的研究可能会关注家庭的症状负担以及未镇静门诊探通术对患者的麻醉和情绪创伤的影响,并进一步探讨每种治疗方法的治疗成本。